Broader screening targeted studies confirmed that not only did IL-6 increase in COVID-19 patients compared to healthy controls, but there was a progressive elevation of this cytokine, CXCL10, and the chemokine GM-CSF in different degrees of COVID-19 severity linked to endothelial damage and thrombosis [61]. This evidence concerns the gene IL6 and COVID-19.